FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1979402451> ?p ?o ?g. }

• W1979402451 endingPage "e554" @default.
• W1979402451 startingPage "e554" @default.
• W1979402451 abstract "To assess the ocular effects and safety profile of chronic sildenafil oral dosing in patients with pulmonary arterial hypertension.12 week, double masked, randomised, placebo controlled, phase III trial with open label extension.53 institutions worldwide.277 adults with idiopathic pulmonary arterial hypertension or pulmonary arterial hypertension associated with connective tissue disease or after congenital heart disease repair (mean pulmonary artery pressure ≥25 mm Hg; pulmonary capillary wedge pressure ≤15 mm Hg at rest).During the double masked study, oral sildenafil 20 mg, 40 mg, or 80 mg or placebo (1:1:1:1) three times daily for 12 weeks was added to baseline drug treatment. In the extension study, the placebo, 20 mg and 40 mg groups received 40 mg three times daily titrated to 80 mg three times daily at week 6. After unmasking, the dose was titrated according to clinical need.Ocular safety (ocular examinations, visual function tests, participants' reports of adverse events, and visual disturbance questionnaire completed by investigators) by treatment group at 12 weeks, 24 weeks, 18 months, and yearly.Findings of the objective assessments-that is, intraocular pressure and visual function tests (visual acuity, colour vision, and visual field)-were similar across groups (20 mg, n=69; 40 mg, n=67; 80 mg, n=71; placebo, n=70). No clinically significant changes occurred between baseline and 12 weeks, except for an efficacy signal in contrast sensitivity for the sildenafil 40 mg three times daily group. In right eyes, changes in intraocular pressure from baseline to week 12 ranged from a mean of -0.5 (95% confidence interval -1.3 to 0.2) mm Hg with placebo, -0.2 (-0.9 to 0.5) mm Hg with sildenafil 40 mg, and -0.1 (-0.7 to 0.5) mm Hg with 80 mg to 0.3 (-0.4 to 0.9) mm Hg with sildenafil 20 mg (the approved dose for pulmonary arterial hypertension). Mean changes from baseline to week 12 in contrast sensitivity in right eyes were -0.02 (SD 0.12) in the sildenafil 20 mg three times daily group compared with -0.05 (0.18) in the placebo group (P=0.044). Percentages of participants with deterioration in visual acuity (Snellen) from baseline to week 12 ranged from 10% (n=7) in the placebo group to 3% (n=2) in the sildenafil 20 mg three times daily group; the same percentages had visual field changes from normal to abnormal during the period in these two groups. The investigators did not deem any findings on colour vision assessment to be clinically significant. Findings of the objective assessments in the 40 mg and 80 mg three times daily sildenafil treatment groups and in left eyes were not substantially different, nor were any measures different throughout the open label extension compared with week 12. However, objective data were limited after month 18, as most participants had missing data or visual parameters were no longer collected by investigators. Incidence of ocular adverse events reported on the case report forms and assessed by the investigator was low with all doses, but a modest, dose related incidence of chromatopsia, cyanopsia, photophobia, and visual disturbance was reported with 80 mg three times daily consistent with the indicated dosing for erectile dysfunction. Retinal haemorrhages, captured on funduscopy, occurred in 2% (4/207) of sildenafil treated participants and none in the placebo group during the double masked study and in 4% (10/259) during the open label extension.Sildenafil dosing up to 80 mg three times daily is safe and well tolerated from an ocular perspective in patients with pulmonary arterial hypertension. Daily chronic dosing in this patient population was not associated with visual change and had no detrimental effect on best corrected visual acuity, contrast sensitivity, colour vision, or visual field, or on slit lamp examinations, funduscopy, or intraocular pressure during the duration of this study.Clinical trials NCT00644605 and NCT00159887." @default.
• W1979402451 created "2016-06-24" @default.
• W1979402451 creator A5008478808 @default.
• W1979402451 creator A5019763377 @default.
• W1979402451 creator A5070428279 @default.
• W1979402451 creator A5089727838 @default.
• W1979402451 creator A5091340144 @default.
• W1979402451 date "2012-02-21" @default.
• W1979402451 modified "2023-09-23" @default.
• W1979402451 title "Ocular safety of sildenafil citrate when administered chronically for pulmonary arterial hypertension: results from phase III, randomised, double masked, placebo controlled trial and open label extension" @default.
• W1979402451 cites W1515739182 @default.
• W1979402451 cites W1552308041 @default.
• W1979402451 cites W1567771840 @default.
• W1979402451 cites W161240884 @default.
• W1979402451 cites W1801877460 @default.
• W1979402451 cites W192975248 @default.
• W1979402451 cites W1963543770 @default.
• W1979402451 cites W1973082528 @default.
• W1979402451 cites W1974268914 @default.
• W1979402451 cites W1979765238 @default.
• W1979402451 cites W1980569331 @default.
• W1979402451 cites W1989661534 @default.
• W1979402451 cites W1989792368 @default.
• W1979402451 cites W1993701077 @default.
• W1979402451 cites W1998326490 @default.
• W1979402451 cites W2000060732 @default.
• W1979402451 cites W2006679838 @default.
• W1979402451 cites W2009276020 @default.
• W1979402451 cites W2014500068 @default.
• W1979402451 cites W2020433703 @default.
• W1979402451 cites W2024343550 @default.
• W1979402451 cites W2028701630 @default.
• W1979402451 cites W2030615514 @default.
• W1979402451 cites W2032682165 @default.
• W1979402451 cites W2035384054 @default.
• W1979402451 cites W2035649273 @default.
• W1979402451 cites W2037582095 @default.
• W1979402451 cites W2040327798 @default.
• W1979402451 cites W2041070057 @default.
• W1979402451 cites W2057622010 @default.
• W1979402451 cites W2058551274 @default.
• W1979402451 cites W2060691366 @default.
• W1979402451 cites W2064918581 @default.
• W1979402451 cites W2068894579 @default.
• W1979402451 cites W2070769478 @default.
• W1979402451 cites W2071628383 @default.
• W1979402451 cites W2075065959 @default.
• W1979402451 cites W2081397635 @default.
• W1979402451 cites W2093529486 @default.
• W1979402451 cites W2093881387 @default.
• W1979402451 cites W2097885824 @default.
• W1979402451 cites W2101552339 @default.
• W1979402451 cites W2104513701 @default.
• W1979402451 cites W2106052836 @default.
• W1979402451 cites W2119854190 @default.
• W1979402451 cites W2121376498 @default.
• W1979402451 cites W2123293252 @default.
• W1979402451 cites W2127697798 @default.
• W1979402451 cites W2128859951 @default.
• W1979402451 cites W2130449101 @default.
• W1979402451 cites W2140476002 @default.
• W1979402451 cites W2142151523 @default.
• W1979402451 cites W2148797779 @default.
• W1979402451 cites W2155911326 @default.
• W1979402451 cites W2166513478 @default.
• W1979402451 cites W2169627979 @default.
• W1979402451 cites W2313158847 @default.
• W1979402451 cites W2400288513 @default.
• W1979402451 cites W2052335241 @default.
• W1979402451 doi "https://doi.org/10.1136/bmj.e554" @default.
• W1979402451 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3283528" @default.
• W1979402451 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22354598" @default.
• W1979402451 hasPublicationYear "2012" @default.
• W1979402451 type Work @default.
• W1979402451 sameAs 1979402451 @default.
• W1979402451 citedByCount "38" @default.
• W1979402451 countsByYear W19794024512012 @default.
• W1979402451 countsByYear W19794024512013 @default.
• W1979402451 countsByYear W19794024512014 @default.
• W1979402451 countsByYear W19794024512015 @default.
• W1979402451 countsByYear W19794024512016 @default.
• W1979402451 countsByYear W19794024512017 @default.
• W1979402451 countsByYear W19794024512018 @default.
• W1979402451 countsByYear W19794024512019 @default.
• W1979402451 countsByYear W19794024512020 @default.
• W1979402451 countsByYear W19794024512021 @default.
• W1979402451 countsByYear W19794024512022 @default.
• W1979402451 crossrefType "journal-article" @default.
• W1979402451 hasAuthorship W1979402451A5008478808 @default.
• W1979402451 hasAuthorship W1979402451A5019763377 @default.
• W1979402451 hasAuthorship W1979402451A5070428279 @default.
• W1979402451 hasAuthorship W1979402451A5089727838 @default.
• W1979402451 hasAuthorship W1979402451A5091340144 @default.
• W1979402451 hasBestOaLocation W19794024511 @default.
• W1979402451 hasConcept C126322002 @default.
• W1979402451 hasConcept C141071460 @default.
• W1979402451 hasConcept C142724271 @default.
• W1979402451 hasConcept C146556889 @default.

• next